1. Home
  2. RPRX vs BAP Comparison

RPRX vs BAP Comparison

Compare RPRX & BAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • BAP
  • Stock Information
  • Founded
  • RPRX 1996
  • BAP 1889
  • Country
  • RPRX United States
  • BAP Peru
  • Employees
  • RPRX N/A
  • BAP N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • BAP Major Banks
  • Sector
  • RPRX Health Care
  • BAP Finance
  • Exchange
  • RPRX Nasdaq
  • BAP Nasdaq
  • Market Cap
  • RPRX 14.0B
  • BAP 14.5B
  • IPO Year
  • RPRX 2020
  • BAP 1995
  • Fundamental
  • Price
  • RPRX $33.88
  • BAP $181.15
  • Analyst Decision
  • RPRX Strong Buy
  • BAP Hold
  • Analyst Count
  • RPRX 5
  • BAP 3
  • Target Price
  • RPRX $41.60
  • BAP $195.67
  • AVG Volume (30 Days)
  • RPRX 4.6M
  • BAP 269.4K
  • Earning Date
  • RPRX 02-11-2025
  • BAP 02-10-2025
  • Dividend Yield
  • RPRX 2.60%
  • BAP 6.73%
  • EPS Growth
  • RPRX N/A
  • BAP 3.65
  • EPS
  • RPRX 1.91
  • BAP 17.61
  • Revenue
  • RPRX $2,263,576,000.00
  • BAP $4,667,680,981.00
  • Revenue This Year
  • RPRX $29.18
  • BAP N/A
  • Revenue Next Year
  • RPRX $9.99
  • BAP $6.05
  • P/E Ratio
  • RPRX $17.69
  • BAP $10.16
  • Revenue Growth
  • RPRX N/A
  • BAP 8.67
  • 52 Week Low
  • RPRX $24.05
  • BAP $153.27
  • 52 Week High
  • RPRX $34.16
  • BAP $200.00
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 80.55
  • BAP 43.51
  • Support Level
  • RPRX $32.28
  • BAP $177.47
  • Resistance Level
  • RPRX $34.20
  • BAP $189.81
  • Average True Range (ATR)
  • RPRX 0.71
  • BAP 5.09
  • MACD
  • RPRX 0.02
  • BAP -0.74
  • Stochastic Oscillator
  • RPRX 89.40
  • BAP 21.57

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About BAP Credicorp Ltd.

Credicorp Ltd is a Peruvian financial services company. It operates in four business lines including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital.

Share on Social Networks: